Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIb Study of the Safety and Efficacy of Nabiximols in Subjects With Spasticity Due to Neuromyelitis Optica Spectrum Disorders: A Double-blind, Randomized, Placebo-Controlled, Crossover Study

NCT05974293 is registered in ClinicalTrials.gov with Michael, Levy M.D.,Ph.D. as lead sponsor.

NCT NCT05974293
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05974293 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIb Study of the Safety and Efficacy of Nabiximols in Subjects With Spasticity Due to Neuromyelitis Optica Spectrum Disorders: A Double-blind, Randomized, Placebo-Controlled, Crossover Study
Lead sponsor
Michael, Levy M.D.,Ph.D.
Phase
Phase 2
Overall status
Withdrawn
Start date
December 31, 2026
Completion date
September 30, 2027
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nmo spectrum disorder, spasticity, muscle